272 related articles for article (PubMed ID: 27886818)
1. Genetic Determinants of P2Y
Cavallari LH; Obeng AO
Interv Cardiol Clin; 2017 Jan; 6(1):141-149. PubMed ID: 27886818
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
3. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Johnson SG; Gruntowicz D; Chua T; Morlock RJ
J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Klein MD; Williams AK; Lee CR; Stouffer GA
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
[TBL] [Abstract][Full Text] [Related]
5. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
6. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
8. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
9. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
Cavallari LH
Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
[TBL] [Abstract][Full Text] [Related]
10. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
11. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
[TBL] [Abstract][Full Text] [Related]
12. Prospective
Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
[TBL] [Abstract][Full Text] [Related]
13. [Genetic variability in the efficacy of clopidogrel].
Kristensen KE; Rasmussen HB; Hansen PR
Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
16. A Genotype-Guided Strategy for Oral P2Y
Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM
N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209
[TBL] [Abstract][Full Text] [Related]
17. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
[TBL] [Abstract][Full Text] [Related]
18. Genotype-guided treatment of oral P2Y
Claassens DM; Ten Berg JM
Pharmacogenomics; 2020 Jan; 21(2):83-86. PubMed ID: 31957547
[No Abstract] [Full Text] [Related]
19. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?
Kassimis G; Stavrou EF; Alexopoulos D; Athanassiadou A
Curr Pharm Des; 2013; 19(13):2489-95. PubMed ID: 23360266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
